drugset / Trial / NCT05223595
A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, open label study to investigate the safety and efficacy of Gentuximab plus Almonertinib in metastatic NSCLC patients with EGFR mutation-positive.
Timeline
- Start
- 2021-04-02
- Primary completion
- 2023-09-30
- Completion
- 2024-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gentuximab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Gentuximab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Background | Almonertinib | Small molecule | 110 mg | Oral |